Morgan Stanley lowered the firm’s price target on Amgen (AMGN) to $329 from $333 and keeps an Equal Weight rating on the shares. A Q3 beat on revenue and EPS benefitted from some one-timers, notes the analyst, who also points out that the company raised FY25 revenue and EPS guidance by about 2% and 1% at the midpoints, respectively. New launches and pipeline progress remain a focus going forward, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s Strong Financial Performance and Growth Potential Drive Buy Rating
- Amgen price target raised to $300 from $280 at Wells Fargo
- Amgen’s Strong Q3 Performance and Promising Pipeline Justify Buy Rating
- Amgen’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
- Amgen Inc. Reports Strong Q3 2025 Financial Results